Speaker illustration

Mr Yang Chen

Mayo Clinic, Rochester (United States of America)

Cardioprotective effects of a novel designer C-type natriuretic peptide-based therapeutic, C53 , for the prevention of post-myocardial infarction heart failure

Event: ESC Congress 2018

Topic: Pharmacotherapy

Session: Targeting reverse remodelling in heart failure

Thumbnail

This platform is supported by

logo Novo Nordisk